Monday, June 15, 2026

#HK CHP continues to actively follow up on a #human case of #H9N2 virus infection and reminds public of possibility of "twin-peaks" for seasonal #influenza and #COVID19 during summer

 


    The Centre for Health Protection (CHP) of the Department of Health (DH) today (June 15) continued to actively follow up on a case of human infection with influenza A (H9) in collaboration with the relevant government departments. 

    Following whole genome sequencing and analysis of the patient's clinical specimens, the virus strain was confirmed to be a low-pathogenic avian influenza A (H9N2) virus

    All of the virus genes were avian in origin and no significant genetic variations were detected

    The patient is currently in stable condition and all six of his household contacts have remained asymptomatic

    As the H9N2 avian influenza virus has long been present in local poultry with low mortality rate for birds, and that the H9N2 avian influenza virus involved in this case has not shown evidence of human-to-human transmission or significant genetic variation, the CHP currently assessed the risk of a local avian influenza pandemic as low

    Nevertheless, the CHP once again strongly urged the public to maintain good personal and environmental hygiene at all times, avoid contact with live poultry, birds or their droppings, thoroughly cook poultry meat and eggs before consumption, and wash hands thoroughly after visiting places where live poultry is sold, so as to reduce the risk of avian influenza infection.

    In addition, with the recent rise in the activity of seasonal influenza and COVID-19, the CHP does not rule out the possibility that the activity of these two respiratory diseases will continue to rise in the coming months, leading to a "twin-peaks" phenomenon. Members of the public, particularly high-risk individuals, are advised to receive vaccination in a timely manner to reduce the risk of severe disease and death.

 

Human infection with influenza A (H9) virus

    In relation to the recent influenza A (H9) infection in a two-year-old boy, the Public Health Laboratory Services Branch of the CHP conducted whole genome sequencing and analysis of the virus, confirming that the virus strain is a low-pathogenic H9N2 avian influenza virus and that no significant genetic variations were detected. 

    The CHP has collected 17 environmental samples from the residence of the patient, the fresh provision shop at Wo Che Market he had visited, as well as a park in Fung Wo Estate

    One sample collected from a metal tray placed at the bottom of a live chicken cage inside the shop that was used to collect chicken droppings was tested positive for the H9 avian influenza virus. 

    The remaining 16 samples tested negative

    The CHP will conduct further analysis on the positive environmental sample. 

    The CHP believed that it is more likely for the boy to have contracted H9 avian influenza by touching a contaminated surface at the fresh food shop selling live poultry in Wo Che Market. Thorough disinfection and cleaning will be conducted at the fresh food shop in question.  

     The patient remains hospitalised in stable condition. His symptoms remain mild. Neither his family members nor the staff at the fresh provision shop concerned have developed any symptoms. The CHP has provided them with preventive medication and will continue to put them under medical surveillance.

     Based on the above epidemiological and virological evidence, the CHP assessed that the recent local case of infection has not changed the current risk level. The risk of an influenza pandemic due to local avian influenza remains low. The Government's response level under the "Preparedness Plan for Influenza Pandemic" remains at "Alert" level.

    Avian influenza viruses are generally classified as highly pathogenic or low pathogenic, and they mainly affect birds and poultry. Birds are also natural hosts for avian influenza viruses. 

    In occasional circumstances, cross-species transmission may occur when human come into close contact with infected poultry or contaminated environments. 

    However, there is currently no scientific evidence to suggest that the existing avian influenza viruses are capable of sustained and efficient human-to-human transmission. 

    No novel influenza virus arising from genetic reassortment between human seasonal influenza viruses and animal influenza viruses has been found either.

    Since 1999, a total of 11 cases of human influenza A (H9N2) have been recorded in Hong Kong, including five local cases and six imported cases. No fatal case has been recorded so far.

     According to data published by the World Health Organization (WHO), more than 160 cases of human infection with influenza A (H9) have been recorded globally in the past decade. The vast majority of patients presented with mild symptoms. As poultry is a natural host of the virus in many regions, sporadic human infections caused by contact with infected poultry or contaminated environments are expected to continue occurring worldwide.

     The CHP will continue to strengthen public education and publicity efforts to reduce the risk of avian influenza infection among the general public. A letter has been issued to all doctors in Hong Kong to update them on the latest situation regarding influenza A (H9), urging them to heighten vigilance and report any suspected cases.

 

Seasonal influenza and COVID-19

     Influenza activity in Hong Kong has increased in recent weeks but remains below the baseline level

    Based on past experience, Hong Kong may experience two influenza seasons each year. The onset of summer influenza season began at a later time than usual last year, and sustained a longer period, extending from early September last year to early January this year, resulting in the absence of the winter influenza season that traditionally occurs in the first quarter of each year. Since the summer influenza season typically occurs between July and August, it cannot be ruled out that it may begin earlier than usual this year.

     Regarding COVID-19, while overall local activity remains at a relatively low level, a slight increase has been recorded continually since early May. 

    The COVID-19 activity levels fluctuate, with an upsurge period seen approximately every six to nine months in recent years. Each upsurge is associated with changes in predominant circulating variants and a decline in community herd immunity. It has been nearly a year since the end of the last periodic upsurge of COVID-19 activity in Hong Kong, and it cannot be ruled out that the overall COVID-19 activity will rise further in the coming one to two months.

 

Government's vaccination programmes

     Vaccination remains the most effective way to prevent seasonal influenza, COVID-19 and its complications. It also reduces the risk of hospitalisation and death.

       The WHO has earlier announced its recommendations for the composition for seasonal influenza and COVID-19 vaccines in the upcoming season. Vaccine manufacturers are currently producing vaccines in accordance with the recommendations. A new batch of seasonal influenza vaccines will arrive in Hong Kong in this September, while COVID-19 vaccines will arrive in the fourth quarter.

     The COVID-19 vaccine provided under the Government's COVID-19 Vaccination Programme (the Programme) for children and adults will expire in mid-July and early September this year respectively. As the production and delivery of COVID-19 vaccines to Hong Kong with the new composition take time, eligible persons will not be able to receive free COVID-19 vaccines through the Programme for a short period during the transition period before a new batch of vaccines arrive in Hong Kong. Therefore, those in need are advised to make appointments as early as possible. Existing vaccination services will continue until the following dates:

         ° Individuals aged six months to 11 years: COVID-19 vaccination services will be available until July 10, 2026.

        ° Individuals aged 12 or above: COVID-19 vaccination services will be available until September 5, 2026.

     In addition, the shelf life of vaccines under the Government's Seasonal Influenza Vaccination (SIV) Programmes will expire at the end of July. The DH launched the 2025/26 SIV Programmes in September last year. With the government's active promotion and the cooperation of various stakeholders, over 2.03 million doses of vaccines have been administered. Members of the public who have not received vaccinations, particularly children, the elderly and chronic disease patients, should receive influenza vaccination as soon as possible.

     To prevent respiratory diseases, members of the public should maintain good personal, hand and environmental hygiene at all times. Members of the public with respiratory symptoms, even if the symptoms are mild, should wear a surgical mask, avoid crowded places and seek medical advice promptly. They should maintain hand hygiene before putting on and after removing a mask. When there is a rise in activity levels of respiratory diseases, high-risk persons should wear surgical masks when visiting public places. The general public should also wear a surgical mask when taking public transport or staying in crowded places.

     The public may visit the CHP's webpages for more information: Avian Influenza Webpage, Avian Influenza Report, COVID-19 Vaccination Programme, Seasonal Influenza Vaccination Programmes, Facebook page and Youtube channel. 

 

Ends/Monday, June 15, 2026 | Issued at HKT 22:10 | NNNN

Source: 


Link: https://www.info.gov.hk/gia/general/202606/15/P2026061500852.htm?fontSize=1

____

Estimation of the #importation #risk of #Bundibugyo virus into the #EU/EEA in June 2026 (ECDC, summary)

 


Assessment | 15 June 2026


    In this report, we present estimates of the probability of importation of Ebola disease caused by Bundibugyo virus (BDBV), into EU/EEA countries for the period 11–25 June 2026 under different assumptions of travel volumes from the areas where most cases were reported from. 

    In addition, we estimate the volume of air travel passengers from this region that would be expected to result in one BDBV importation.


Key findings

    ° The ongoing outbreak of the Bundibugyo virus (BDBV) in the Democratic Republic of the Congo (DRC) has raised some concerns about the BDBV importation risk into the European Union/European Economic Area (EU/EEA).

    ° Based on mathematical modelling, we estimate approximately one importation per 23 000 travellers (90% Uncertainty Interval, UI: 13 000 – 54 000) from the main outbreak region (North Kivu and Ituri, DRC) to the EU/EEA.

    ° We estimate the probability of at least one BDBV importation into the EU/EEA from 11–25 June 2026 to be 0.45% (90% UI: 0.20%-0.85%), under the hypothetical assumption that 100 people travel from the outbreak region to the EU/EEA during this period. 

    ° We consider 100 travellers to be a conservative upper estimate based on available historical flight data and the closure of multiple airports in the proximity of the outbreak region. The true probability of importation is therefore likely to be lower.

    ° These estimates apply to travellers from the general population in the outbreak region. 

    ° The risk of importation associated with returning healthcare workers deployed to support the outbreak response is beyond the scope of this report.


Conclusions

    ° While sporadic BDBV importations into the EU/EEA cannot be ruled out, mathematical modelling suggests that the probability of importation from 11 to 25 June is very low

    ° These results apply to importation of BDBV from the general population of Ituri and North Kivu

    ° Humanitarian aid workers or healthcare care personnel returning from the outbreak region to the EU/EEA, who we assume would be medically evacuated from the affected areas with application of appropriate infection prevention and control measures, need to be considered separately.

    ° As one BDBV importation is expected per 24 000 travellers from the outbreak region, the vast majority of travellers will not be infected

    ° However, since early symptoms of BDBV infections overlap with many other conditions, a potentially large number of travellers will show similar symptoms as BDBV infections without being infected with BDBV (i.e. false positives). 

    ° Therefore, entry screening strategies based solely on symptom detection are likely to have low specificity, which will lead to unnecessary isolation, testing, and follow-up of a potentially large number of individuals per true case.

    ° The presented importation probabilities are model estimates, which are subject to several limitations and are based on currently observed trends of BDBV infections in DRC. 

    ° If there are substantial changes in the epidemiological situation, such as spread to other regions, then the results of this output need to be reassessed.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/publications-data/estimation-importation-risk-bundibugyo-virus-eueea-june-2026

____

#Bhutan - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 


A poultry farm in Samdrupjongkhar Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7623

____

#Denmark - #Influenza A #H5 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


According to article 10.4.1.4 of the Terrestrial Animal Health Code, Member Countries should not impose bans on the trade in poultry commodities in response to notification on the presence of any influenza A virus in birds other than poultry.

A wild black-headed gull in Stevns.

Source: 


Link: https://wahis.woah.org/#/in-review/7614

____

#Slovenia - Equine #influenza #H3N8 virus (Inf. with) - Immediate notification [FINAL]

 


Domestic Equidae spp. in Osrednjeslovenska Region.

Source: 


Link: https://wahis.woah.org/#/in-review/7621

____

#Sweden - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification



{Helsingborg Region} This is a farm with mallards for restocking for game and breeding for this purpose. The mallards showed an increse in mortality. Euthanasia is ongoing. 

Source: 


Link: https://wahis.woah.org/#/in-review/7622

____

#Risk #classification and contact #tracing of #travellers returning from affected areas – #Ebola disease outbreak 2026 caused by #Bundibugyo virus (ECDC, edited)

 


Public health guidance


    This table and accompanying algorithm provide guidance for EU/EEA public health authorities, decision-makers, and healthcare professionals on risk categorisation and management of individuals potentially exposed to Ebola disease. 

    The guidance applies to contacts of confirmed or probable cases following travel to, residence in, or work in Ebola outbreak-affected areas, as well as to occupational exposures.

    As long as an outbreak is ongoing, individuals arriving from affected regions may develop Ebola disease after entering non-affected countries. Minimising transmission relies on rapid case detection and isolation, effective contact tracing, and strict infection prevention and control (IPC) measures.

    Given the severity of Ebola disease, timely identification and risk-based management of exposed individuals is essential. Early detection of symptomatic contacts enables prompt isolation, testing, and clinical care, thereby reducing the interval between symptom onset and case recognition. This approach minimises opportunities for onward transmission and strengthens outbreak control.


Risk exposure classification and proposed measures

{Risk exposure category

    ° Exposure type and examples

        § Proposed measures}


No exposure

    ° No exposure to symptomatic cases or persons under investigation - E.g. General returning travellers from the affected areas, without any exposure

        § Provision of clear, accurate, and up‑to‑date information about Ebola disease, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival, including targeted behavioural guidance.


Low-risk occupational exposure

    ° Protected occupational exposure*
    E.g. Properly protected (personal protective equipment – PPE - used) contact with suspected/confirmed Ebola disease case, bodily fluids, fomites (e.g. linens), or virus samples (lab specimens, cultures). Doffing of PPE presents an elevated risk of self-contamination if strict measures are not taken to doff PPE per a controlled doffing protocol under the guidance and observation of a trained observer.

    {*} Contact using appropriate PPE is not considered significant exposure, however, context regarding PPE protocols used and their adherence should always be considered.

        § Self- monitoring (passive monitoring) for 21 days after last exposure: temperature and symptoms check twice a day

        § Provision of clear, accurate, and up‑to‑date information about Ebola disease, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival including targeted behavioural guidance.


Low-risk exposure

    ° Contact with symptomatic case (non-fluid exposure) 
    E.g. Close face-to-face contact (e.g. within <1 meter, sharing seating or public transport (incl. airplane), receptionist duties, household/classroom/office contact with a feverish or symptomatic person who has suspected/confirmed Ebola disease not coughing, vomiting, bleeding, or with diarrhoea

        § Self- monitoring (passive monitoring) for 21 days after last exposure: temperature and symptoms check twice a day

        § Provision of clear, accurate, and up‑to‑date information about Ebola disease, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival including targeted behavioural guidance.

        § Public health authorities may indicate more actions, depending on the circumstances 


High-risk exposure

    ° Close contact without appropriate PPE / unprotected exposure
    E.g. Close face-to-face contact (e.g. within <1 meter) or any direct, unprotected or improperly protected contact with a person who has suspected/confirmed Ebola disease, their bodily fluids, contaminated fomites, or infectious laboratory material—particularly when the person is symptomatic (e.g. coughing, vomiting, bleeding, or has diarrhoea)—or direct contact with materials contaminated by bodily fluids, without appropriate personal protective equipment, including eye protection.

    ° Unprotected sexual contact with someone who has Ebola disease or a survivor without confirmed negative semen RT-PCR tests (2 negative tests ≥1 week apart)

    ° Burial exposure 
    E.g. Participation in burial rites with direct contact of the remains or bodily fluids without PPE

    ° Percutaneous injury (e.g. with needle) or mucosal exposure to laboratory specimens suspected of containing orthoebolavirus or to bodily fluids, tissues, or specimens

        § Active monitoring for 21 days following last exposure:

             - Temperature and symptoms check twice a day with active reporting to public health authorities or after active contact by public health authorities

            - Remain reachable

            - No travel abroad

            - Consider restriction of social interactions 

            - Consider restrictions of engagement in clinical activities and follow national occupational health plan

        § Provision of clear, accurate, and up‑to‑date information about Ebola, including transmission risks, symptoms, and required monitoring after potential exposure.

        § Instructions for action if symptoms develop after arrival including targeted behavioural guidance.

        § Public health authorities may indicate more actions, depending on the circumstances 

        § In case of clearly established percutaneous injury or mucosal exposure: restrictions of social interactions/contacts and movements as a precautionary measure. 

___

    Other types of ‘high-risk’ exposure are beyond the scope of this document, for example: 

    Direct contact with bushmeat (e.g. eating raw bushmeat, carving up the animal, direct contact with the animal’s blood or bodily fluids), bats, rodents, primates living or dead, in or from Ebola disease-affected areas 

    Exposure through breastfeeding

Note: This classification is based on selected examples of exposures and is not exhaustive. 

(...)

Source: 


____

Sunday, June 14, 2026

Procession of the True Cross (Procession in St. Mark's Square), Gentile Bellini (1496)

 


{Click on Image to Enlarge}

Public Domain.

Source: 


Link: https://www.wikiart.org/en/gentile-bellini/processione-della-vera-croce-a-piazza-san-marco-a-venezia-1496

____

Saturday, June 13, 2026

#Ebola disease caused by #Bundibugyo virus, #DRC & #Uganda (WHO D.O.N., June 13 '26): 676 confirmed cases and 136 deaths in DRC; 19 case in Uganda

 


Situation at a glance

    The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo continues to evolve rapidly, with increasing case numbers and geographic spread

    As of 10 June, a cumulative of 676 confirmed cases, including 136 deaths, have been reported from the Democratic Republic of the Congo. 

    As of 11 June, Uganda has reported 19 confirmed cases including two deaths, as well as one probable case who has died. 

    In Uganda, the outbreak remains epidemiologically linked to transmission originating in the Democratic Republic of the Congo, with evidence of both imported infections and secondary transmission among contacts and healthcare workers

    Uganda has not reported any new cases in the past six days. 

    National authorities in the two affected countries, in collaboration with WHO and partners, are implementing a comprehensive package of response measures. 

    A regional preparedness and prioritization framework continues to guide readiness activities across the African Region.


Description of the situation

    Since the last Disease Outbreak News was published on 8 June 2026, the number of confirmed cases and deaths have increased rapidly in the Democratic Republic of the Congo

    In total, 695 confirmed cases; 676 from the Democratic Republic of the Congo and 19 from Uganda; and 138 deaths including  two from Uganda, have been reported from both countries, while at least 37 people have recovered from the disease. 

(...)


Democratic Republic of the Congo

    Since 8 June, an additional 161 confirmed cases, including 45 confirmed deaths, have been reported from the Democratic Republic of the Congo. 

    The increase is in part due to the scale up of testing and diagnostic capacities, enabling testing of the backlog of previously collected samples. 

    As of 10 June 2026, a total of 676 confirmed cases including 136 deaths (CFR 20.1%) have been reported from the Democratic Republic of Congo. 

    The reported CFR is likely an underestimation, as many deaths that occurred before the outbreak declaration remain under investigation. 

    So far, 32 patients have recovered

    Cases have been reported from 29 health zones (HZ) from Ituri (19/36 HZ), North Kivu (9/35 HZ) and South Kivu provinces (1/34 HZ) [1]. 

    Sixteen confirmed cases have been reported among health and care workers to date.

    The outbreak remains concentrated in Ituri Province, which accounts for 93% (629) of the confirmed cases with a CFR of 17.3% (109/629). 

    The highest number of confirmed cases in Ituri Province are reported from Bunia (185 cases), Rwampara (137 cases), Mongbwalu (132 cases), and Nyankunde (33 cases) health zones. 

    While the epicentre remains Ituri, there has been significant geographic expansion of health zones with confirmed cases since 8 June, with confirmed cases in additional four health zone as of 10 June. 

    Of the total confirmed cases, 94 are awaiting distribution by HZ.

    As of 10 June, 5768 contacts have been identified and are under follow-up across Ituri (4703), North Kivu (841), and South Kivu (224) provinces. 

    Of these, 4141 contacts have been followed up, corresponding to follow-up rates of 71.4% in Ituri, 71% in North Kivu, and 83.5% in South Kivu.

    The outbreak is unfolding in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations. 

    These dynamics, combined with increasing security-related incidents affecting health facilities, have posed additional operational challenges in affected provinces, such as constrained access for response teams, disrupted surveillance and response activities, and heightened risk of undetected transmission. These conditions underscore the need for response efforts to be led by local leaders and anchored in communities. 

___

Figure 2: Number of confirmed cases (n = 676) in the Democratic Republic of the Congo, by date of reporting as of 10 June 2026


{Click on Image to Enlarge}
__


NB: Newly reported confirmed cases/deaths may be part of the back log of samples and therefore not necessarily newly acquired infections. 


Uganda

    Since the last update dated 8 June, no additional confirmed cases or death have been reported from Uganda. 
    
    As of 10 June 2026, a cumulative of 19 confirmed cases including two deaths in imported cases, and one probable case who has died, have been reported. 

    Of the confirmed cases, 14 cases are imported and five are secondary transmission among contacts and health workers following cases imported from the Democratic Republic of the Congo. 

    The cases have been reported from two districts, Kampala and Wakiso, both part of the Kampala Metropolitan Area. 

    To date, there has been no documented community transmission in Uganda. 

    Exposure risks are associated with healthcare settings and cross-border movements. Five recoveries have been reported to date.

    Of the 820 contacts listed as of 11 June, a total of 409 contacts are under active follow up and 394 contacts have completed their 21-day follow-up period. 

___

Figure 3: Number of confirmed cases (n = 19) in Uganda by date of reporting as of 11 June 2026 


{Click on Image to Enlarge}
__

Epidemiology

    Bundibugyo virus disease (BVD) is a severe and often fatal form of Ebola disease caused by the Bundibugyo virus, one of the Orthoebolavirus species. It is a zoonotic disease, with fruit bats suspected to be the natural reservoir. Human infection is thought to occur through close contact with the blood or secretions of infected wildlife, such as bats or non-human primates, and it subsequently spreads from person to person through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or contaminated surfaces or items. Transmission is particularly amplified in health-care settings when infection prevention and control (IPC) measures are inadequate, and during unsafe burial practices involving direct contact with the deceased.

    The incubation period for BVD ranges from two to 21 days, and individuals are not infectious until symptom onset. Early symptoms such as fever, fatigue, muscle pain, headache, and sore throat, are non-specific, which complicates clinical diagnosis and can delay detection. These symptoms then progress to gastrointestinal symptoms, organ dysfunction, and in some cases haemorrhagic manifestations. Case fatality rates in the past two BVD outbreaks, reported in Uganda and in the Democratic Republic of the Congo in 2007 and 2012 were 30% and 50% respectively.

    Differentiating BVD from other endemic febrile illnesses such as malaria is challenging without laboratory confirmation using PCR or antigen/antibody-based assays. Control relies on rapid case identification, isolation and care, contact tracing, safe burials, and strong community engagement, as no approved vaccines or specific treatments currently exist for BVD.


Public health response

    Health authorities in the Democratic Republic of the Congo and Uganda, in collaboration with WHO and partners, are implementing comprehensive public health measures including implementing the continental response plan, engaging donors and mobilizing additional resources to address critical funding gaps and sustain response operations across affected and at-risk areas.

    In the Democratic Republic of the Congo, a subnational risk-stratification analysis has been conducted to further inform the operational response priorities. According to the latest analysis dated 8 June, 159 health zones are categorized as affected or at risk. This underscores the massive geographic scale of response needed to control this outbreak

    For further information about public health response actions by the respective Ministry of Health, WHO, and partners, please refer to the latest situation reports published by the WHO Regional Office for Africa Ebola Bundibugyo Virus Disease Outbreak Democratic Republic of the Congo | Uganda Weekly External Situation Report 04, Data as of 7 June 2026 | WHO | Regional Office for Africa 

    Following the recommendations of WHO advisory groups on candidate therapeutics to be considered for a clinical trial, WHO, Africa CDC and other partners are supporting the Democratic Republic of the Congo and Uganda in implementing the clinical trial. This include using MBP134 and REGN3479 for treatment, and using obeldesivir for post-exposure prophylaxis, ensuring the highest ethical standards under the leadership of the national health authorities and in close consultation with affected communities.

    The protocol for the trial has been submitted and is under review by ethics committees and regulatory authorities of the countries. More coordination, and research and development funding, are needed to ensure timely access to candidate therapeutics.


WHO risk assessment

    On 6 June 2026, WHO reassessed the risk of the outbreak of BVD to incorporate newly available information and align with the WHO Temporary Recommendations. The risk for countries sharing land borders with countries with documented Bundibugyo virus (BVDV) detection, currently the Democratic Republic of the Congo and Uganda, has been separated out from the risk for other countries in the African Region.

    The risk in the Democratic Republic of the Congo remains assessed as very high due to ongoing transmission and the continued expansion of the outbreak into new health zones, increasing the potential for further national and regional spread.

    The risk in Uganda is still assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor, historically affected by Ebola outbreaks, including Bundibugyo and Sudan virus disease outbreaks.

    The risk for countries with land borders adjoining countries with documented BDBV detection, is assessed as high due to sustained population mobility linked to cross-border trade and mining activities, variation in capacities and experience of BVD response, and variable levels of readiness.

    The risk for the rest of the Africa region and at the global level is assessed as low.

    For further information, please see the WHO Rapid Risk Assessment – Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo, Uganda and countries with land borders adjoining countries with documented BDBV detection v3.


WHO advice

    WHO advises against any restriction of travel to, or trade with, the Democratic Republic of the Congo or Uganda based on the currently available information. WHO continues to closely monitor and, where necessary, verify travel and trade measures in relation to this event.

    For further information on the considerations for implementing border health and international travel-related temporary recommendations, please see the relevant technical note issued on 26 May 2026.

    The temporary recommendations issued to State Parties on 22 May 2026 underscore the importance of coordinated outbreak control, enhanced cross‑border collaboration, and sustained surveillance and preparedness to prevent further regional spread and ensure an effective public health response.

    WHO has convened several technical advisory groups, including the Strategic Advisory Group of Experts on Immunization (SAGE) to assess candidate vaccines and therapeutics for BVD. Key recommendations made are available in the news release published on 28 May 2026.

(...)

Citable reference: World Health Organization (13 June 2026). Disease Outbreak News; Bundibugyo Virus Disease, Democratic Republic of the Congo and Uganda. Available at https://www.who.int/emergencies/disease-outbreak/news/item/2026-DON607

Source: 


____


#Genomic #wastewater #surveillance of seasonal and #zoonotic #influenza A viruses in #California during the 2024-2025 flu season

 


Abstract

Wastewater genomic surveillance provides an opportunity to detect human and animal influenza A virus (IAV). We aimed to implement an IAV genomic surveillance framework agnostic to subtype, which enables recovery of IAV from multiple hosts and estimation of proportions across subtypes. We conducted IAV genomic surveillance in wastewater during the 2024-2025 flu season at multiple sites in California and compared these data with available human clinical IAV sequences and test positivity. We applied a custom whole-genome, multi-host IAV probe enrichment panel and adapted our custom expectation-maximization (EM) algorithm to deconvolute IAV mixtures in wastewater and infer subtype relative abundances. Absolute IAV concentrations were quantified using RT-PCR-based assays. H5N1 wastewater and clinical sequences were further characterized by constructing a whole-genome maximum-likelihood phylogenetic tree. Finally, we performed variant analysis to examine amino acid substitutions detected in wastewater. Our IAV probe enrichment method and EM algorithm successfully enriched all eight segments of three circulating IAV subtypes and accurately estimated subclade relative abundances for mixed IAV samples. Seasonal human H1N1pdm09 and H3N2 were detected throughout the study period from both wastewater and clinical sequencing data, with H1N1 subclades 6B.1A.5a.2a.1 and 6B.1A.5a.2a co-circulating, and H3N2 dominated by subclade 3C.2a1b.2a.2a.3a.1. Wastewater surveillance consistently detected H5N1 clade 2.3.4.4b across three monitored wastewater sites, while clinical H5N1 detections, from anywhere in CA, were sporadic and rare. Whole-genome phylogenetic analysis revealed that wastewater H5N1 sequences clustered with reference sequences associated with dairy cow and avian infections, while all human clinical H5N1 sequences clustered exclusively with reference sequences associated with dairy cow infections. Amino acid substitutions were identified across viral segments, and no mutations associated with mammalian adaptation were observed from wastewater samples.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.06.10.26355323v1

____

Seasonal #vaccine-induced #immunity shows preserved cross-reactivity to #H3N2 subclade K in adults

 


Summary

Background

Influenza A subclade K viruses caused high infection rates in the 2025/2026 Northern Hemisphere season, raising concerns about antigenic drift and reduced vaccine effectiveness.

Methods

We measured antibody responses in matched human pre- and post-vaccination sera, selected from two observational cohort studies of adults, against both a vaccine-like as well as subclade K isolates.

Findings

Pre-existing immunity to subclade K variants was noted with seasonal influenza vaccination further boosting titres two-fold against subclade K and three-fold against the vaccine-like strain, consistent with limited antigenic divergence between subclade K isolates and the vaccine. These findings contrast with ferret-based predictions of marked antigenic drift and align with the observed vaccine effectiveness in adults.

Interpretation

Our results underscore the importance of incorporating human serologic data in influenza surveillance to better inform vaccine strain selection and anticipate vaccine performance in immunologically experienced populations.

Funding

NIAID Centers for Excellence in Influenza Research and Response (75N93021C00014); NIAID VIVA HIPC (U19 AI168631); Mount Sinai Center for Vaccine Research and Pandemic Preparedness; institutional support from the Mount Sinai Center for Vaccine Research and Pandemic Preparedness and the Medical University of Vienna.

Source: 


Link: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00203-3/fulltext

____

History of Mass Transportation: The Class 88 Diesel Shunter of Romanian Railways

 


{Click on Image to Enlarge}

By Stefan Puscasu - http://cfr.stfp.net/?sta=1&class=88&ppr=5, Public Domain, https://commons.wikimedia.org/w/index.php?curid=8459468

Source: 


Link: https://en.wikipedia.org/wiki/Rolling_stock_of_the_Romanian_Railways#/media/File:Locomotiva_CFR_clasa_88.jpg

____

#Coronavirus Disease Research #References (AMEDEO, June 13 '26)

 


    Clin Infect Dis

  1. BRITT NS, Khader K, He T, Prinzi AM, et al
    Clinical Impact of the BIOFIRE(R) FILMARRAY(R) Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study.
    Clin Infect Dis. 2026 Jun 12:ciag328. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  2. NERBY J, Berg W, McFarren M, Rhame F, et al
    Collaborative approaches to masking: statewide threshold development and performance across three respiratory seasons.
    Infect Control Hosp Epidemiol. 2026 Jun 11:1-7. doi: 10.1017/ice.2026.10487.
    PubMed         Abstract available


    Int J Infect Dis

  3. CHEN H, Manu EK
    Shifting patterns of acute respiratory infection mortality in Australia: Changing contributions of COVID-19, influenza and respiratory syncytial virus and persistent Indigenous inequalities.
    Int J Infect Dis. 2026 Jun 8:108866. doi: 10.1016/j.ijid.2026.108866.
    PubMed         Abstract available


    Intensive Care Med

  4. MEYBOHM P, Baron DM, Fries D, Lasocki S, et al
    Patient blood management in general intensive care patients.
    Intensive Care Med. 2026 Jun 8. doi: 10.1007/s00134-026-08491.
    PubMed         Abstract available


    J Infect

  5. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
    Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
    J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
    PubMed         Abstract available

  6. WANG X, Yin J, Xu B, Guanhua X, et al
    Clinical epidemiological characteristics of hospitalized pediatric Mycoplasma pneumoniae pneumonia in China.
    J Infect. 2026 Jun 10:106793. doi: 10.1016/j.jinf.2026.106793.
    PubMed         Abstract available

  7. TRUONG T, Radin JM, Li L, Ordonez-Mena JM, et al
    Burden and economic impact of RSV hospitalisations among English adults, 2023/24.
    J Infect. 2026;93:106792.
    PubMed         Abstract available


    J Med Virol

  8. USHIJIMA H, Onda-Shimizu Y, Kotaki T, Nishimura S, et al
    Co-Circulation and Mixed Infections of Classic and Melbourne Human Astroviruses Among Pediatric Acute Gastroenteritis Patients in Japan, 2018-2024.
    J Med Virol. 2026;98:e71002.
    PubMed         Abstract available

  9. AYDIN U, Duzenci D, Akkoc RF, Karatas A, et al
    Serum Histatin Levels in COVID-19: Association With Disease Severity and Immune Status.
    J Med Virol. 2026;98:e71009.
    PubMed         Abstract available

  10. CHEN R, Kong W, Li C, Zhang J, et al
    TXD-198 Exhibits Inhibitory Activity Against SARS-CoV-2 by Upregulating ANO1.
    J Med Virol. 2026;98:e71004.
    PubMed         Abstract available

  11. DENG J, Lin Q, Zeng Z, Huang H, et al
    Post-Pandemic Influenza Resurgence in Guangzhou, China: Impact of COVID-19 Interventions and Immune Alterations.
    J Med Virol. 2026;98:e71012.
    PubMed         Abstract available

  12. FU JYL, Lim SK, Jalalonmuhali M, Bador MK, et al
    Immune Pressure From Plasma From Immunocompromised and Healthy Individuals Drives Differential SARS-CoV-2 Evolution and Escape Mutation Emergence.
    J Med Virol. 2026;98:e71016.
    PubMed         Abstract available


    J Travel Med

  13. LUBBERT C, Fruhwein M, Dinjer CS, Machler C, et al
    Assessment of the healthcare burden of dengue disease in Germany: a retrospective analysis of statutory health insurance data (2014-2023).
    J Travel Med. 2026 Jun 11:taag047. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  14. YANG Y, Su Z, Zhang X, Tan Y, et al
    PPP2R5B regulates ANPEP expression and TGEV entry via dephosphorylation of HSF1 at Ser304/Ser308.
    J Virol. 2026 Jun 11:e0016626. doi: 10.1128/jvi.00166.
    PubMed         Abstract available

  15. YO MS, Kaku Y, Kosugi Y, Tolentino JE, et al
    Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.
    J Virol. 2026 Jun 10:e0035226. doi: 10.1128/jvi.00352.
    PubMed         Abstract available

  16. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available

  17. ARTUSA V, Limanaqi F, Santacroce E, Clerici M, et al
    Alpha-synuclein at the crossroads of host-virus interactions: immunological roles beyond the nervous system.
    J Virol. 2026 Jun 9:e0019126. doi: 10.1128/jvi.00191.
    PubMed         Abstract available

  18. VARGAS DA, Albornoz LL, Pena-Morales M, Ortiz Rojas HJ, et al
    Within-host SARS-CoV-2 diversity in immunocompromised patients during acute infection.
    J Virol. 2026 Jun 9:e0222425. doi: 10.1128/jvi.02224.
    PubMed         Abstract available

  19. YU H-M, Zhu M-L, Zhao Y-L, Tan J-X, et al
    Research progress on the association between viruses and cardiac diseases.
    J Virol. 2026 Jun 9:e0038326. doi: 10.1128/jvi.00383.
    PubMed         Abstract available

  20. LI S, Luo H, Zhang K, Wu C, et al
    The cholesterol transporter Niemann-Pick C1 facilitates the entry of porcine epidemic diarrhea coronavirus.
    J Virol. 2026 Jun 9:e0030126. doi: 10.1128/jvi.00301.
    PubMed         Abstract available

  21. ZHANG Q, Xin J, Wang C, Zhang X, et al
    Cleavage of TOM1 by the SARS-CoV-2 main protease NSP5 prevents autophagic degradation of viral envelope.
    J Virol. 2026 Jun 12:e0043426. doi: 10.1128/jvi.00434.
    PubMed         Abstract available


    Lancet Infect Dis

  22. XIE Y, Choi T, Al-Aly Z
    Seasonal influenza versus COVID-19 hospitalisation risk during the 2025-26 influenza season.
    Lancet Infect Dis. 2026 Jun 10:S1473-3099(26)00289.
    PubMed        


    Travel Med Infect Dis

  23. MIHAI I, Bonnaud L, Arregle F, Doudier B, et al
    Purulent meningococcal pericarditis with cardiac tamponade in a Hajj pilgrim: A diagnostic challenge of anchoring bias on MERS-CoV.
    Travel Med Infect Dis. 2026;72:103001.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, June 13 '26)

 


    Arch Virol

  1. SMATTI MK, Al-Khatib H, Suleman M, Nizar M, et al
    Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.
    Arch Virol. 2026;171:198.
    PubMed         Abstract available


    J Infect

  2. HARRIS R, Thirard R, McBrien C, Middleditch A, et al
    Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial.
    J Infect. 2026 Jun 4:106784. doi: 10.1016/j.jinf.2026.106784.
    PubMed         Abstract available

  3. CORRAO G, Sguazzini E, Gori A, Monti E, et al
    All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy.
    J Infect. 2026;93:106769.
    PubMed         Abstract available

  4. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
    Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
    J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
    PubMed         Abstract available


    J Infect Dis

  5. LIU F, Gross FL, Li Z, House SL, et al
    Birth cohort effects in adults associated with influenza A(H1N1)pdm09 vaccine effectiveness.
    J Infect Dis. 2026 Jun 8:jiag294. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  6. LIU Z, Fan M, Zeng Y, Zheng Y, et al
    Gga-miR-92-targeted TNFRSF1B inhibits the replication of influenza A virus by degrading TRAF3.
    J Virol. 2026 Jun 12:e0067426. doi: 10.1128/jvi.00674.
    PubMed         Abstract available

  7. XU S, Zhang Q, Xie X, Zhou M, et al
    A neutralizing nanobody targeting a conserved lateral patch on HA1 confers protection against multiple H7 avian influenza viruses.
    J Virol. 2026 Jun 11:e0056326. doi: 10.1128/jvi.00563.
    PubMed         Abstract available

  8. PENG M, Liu L, Li X, Yu X, et al
    Pre-pandemic contraction, phase-specific rate variation, and site-specific antigenic adaptation shape influenza A(H3N2) evolutionary dynamics in Hubei, China.
    J Virol. 2026 Jun 10:e0055626. doi: 10.1128/jvi.00556.
    PubMed         Abstract available


    PLoS Comput Biol

  9. LIN Z, Gao Y, Sun W
    Supervised deep learning with gene functional annotation for cell classification.
    PLoS Comput Biol. 2026;22:e1014327.
    PubMed         Abstract available

  10. KWON J, Li K, Warren JL, Pandya S, et al
    Utilizing virus genomic surveillance to predict vaccine effectiveness.
    PLoS Comput Biol. 2026;22:e1014329.
    PubMed         Abstract available


    PLoS One

  11. TAM VCW, Yeung NCY, Kwok AWL
    Getting over the hurdles to save lives: Incorporating perceived barriers into theory of planned behaviour (TPB) model to predict stated intention among Hong Kong trained laymen.
    PLoS One. 2026;21:e0350392.
    PubMed         Abstract available

  12. KONDO K, Morita I, Sakuma S, Ohsawa I, et al
    Changes in tobacco sales before, during, and after the COVID-19 pandemic in Japan: An interrupted time series analysis.
    PLoS One. 2026;21:e0350820.
    PubMed         Abstract available

  13. WOODGATE RL, Mary-Quigley L, Bell A, Bennett M, et al
    Youth's mental health journeys through the COVID-19 pandemic using arts-based methods in virtual environments.
    PLoS One. 2026;21:e0349860.
    PubMed         Abstract available

  14. KARAMI B, Rezaeian S, Bagherinia M, Shakiba E, et al
    Social support and health related quality of life among older people in covid-19 pandemic: The mediating role of resilience.
    PLoS One. 2026;21:e0342982.
    PubMed         Abstract available

  15. YANG RJ, Wang M, Lyu L, You JL, et al
    Pathogen spectrum and epidemiology of respiratory tract infections in Quzhou, Eastern China, from November 2023 to July 2024: A post?COVID?19 surveillance study.
    PLoS One. 2026;21:e0346441.
    PubMed         Abstract available

  16. BOLSHOV O, Chumachenko D
    Reinforcement learning for policymaking in epidemic control: A scoping review.
    PLoS One. 2026;21:e0351176.
    PubMed         Abstract available

  17. LIU C, Liu H, Wei Y, Ye J, et al
    Modeling the effects of meteorological factors and media-driven public awareness on seasonal influenza outbreaks.
    PLoS One. 2026;21:e0342962.
    PubMed         Abstract available

  18. LIU F, Lai T, Xu W, Li G, et al
    ViralMultiNet: A structure-aware multimodal framework for viral protein function prediction in wastewater surveillance.
    PLoS One. 2026;21:e0349393.
    PubMed         Abstract available

  19. MOUNCHID PM, Shukla S, Steinert JI
    The interplay of economic shocks and cultural practices in child marriage: Comparative evidence from India and Zambia during the COVID-19 pandemic.
    PLoS One. 2026;21:e0346851.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  20. ZHU Z, Fragkias M, Suh JW, McCoshan E, et al
    The Urban Pulse: Diagnosing the urbanization process as spiky, cyclical, and asynchronous.
    Proc Natl Acad Sci U S A. 2026;123:e2537770123.
    PubMed         Abstract available

  21. SKELLY AN, Fan C, Keeffe JR, Okten AB, et al
    mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.
    Proc Natl Acad Sci U S A. 2026;123:e2536870123.
    PubMed         Abstract available


    Vaccine

  22. WU X, Tao Y, Sun Y, Chen J, et al
    Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data.
    Vaccine. 2026;88:128782.
    PubMed         Abstract available

  23. BIETZ A, Sandow P, Hartmann C, Steffan L, et al
    Real-time in-season monitoring of adult influenza vaccination coverage rates in Germany: results from a repeated cross-sectional online survey.
    Vaccine. 2026;88:128765.
    PubMed         Abstract available

  24. SONG L, He G, Cui Y, Tan R, et al
    Optimized flagellin enhances systemic and mucosal immune responses induced by SARS-CoV-2 virus-like particle vaccines.
    Vaccine. 2026;87:128767.
    PubMed         Abstract available

  25. FAIJUE DD, Bouaddi O, Segui AO, Morias B, et al
    Catch-up and life-course vaccination policies for adult and adolescent migrants in low-and-middle income countries: A policy analysis.
    Vaccine. 2026;85:128645.
    PubMed         Abstract available

  26. FORNS J, Pajouheshnia R, Aurelius T, Bouck Z, et al
    Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.
    Vaccine. 2026;86:128723.
    PubMed         Abstract available

  27. POWELL A, Suwalowska H, Sankoh O, Guo C, et al
    Recent enough to matter: Perceived temporal proximity, anxiety, and COVID-19 vaccine intent.
    Vaccine. 2026;85:128717.
    PubMed         Abstract available

  28. DALEXIS RD, Beogo I, Kibret TC, Cenat JM, et al
    Racial disparities in coverage and determinants of childhood diphtheria, tetanus, and pertussis (DTaP) vaccination in Canada: a post-COVID-19 pandemic analysis.
    Vaccine. 2026;85:128679.
    PubMed         Abstract available

  29. KOIRALA A, Prasad SA, Tjiam MC, Britton PN, et al
    SARS-CoV-2 Ancestral and Omicron variant immunity in Australian children in 2023, a seroprevalence study.
    Vaccine. 2026;85:128705.
    PubMed         Abstract available

  30. XU Y, Nyberg F, Marking U, Gisslen M, et al
    Rare adverse events after COVID-19 vaccination among Swedish older adults-evidence from a nationwide register-based study.
    Vaccine. 2026;85:128724.
    PubMed         Abstract available

  31. DANCHIN M, Rak A, Vasiliadis S, Wang B, et al
    Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice experiment.
    Vaccine. 2026;85:128710.
    PubMed         Abstract available

  32. KOHLI M, Maschio M, Lee A, Kissler S, et al
    The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.
    Vaccine. 2026;85:128687.
    PubMed         Abstract available

  33. TRANG TPH, Bazelier MT, Klungel OH, Bots SH, et al
    Quality and methodological heterogeneity of COVID-19 vaccine safety studies focusing on the myocarditis safety signal: A systematic review, meta-analysis and meta-regression.
    Vaccine. 2026;85:128722.
    PubMed         Abstract available

  34. WANG R, Zhao Y, Yang J, Luo R, et al
    Systemic BCG administration induces transcription factor signature in CD4(+) T cells that cooperates with IL-12 signaling to drive antiviral Th1 differentiation.
    Vaccine. 2026;85:128720.
    PubMed         Abstract available


    Virology

  35. KOVACS E, Rios Carrasco M, Guerreiro Cabana MF, de Vries RP, et al
    H5N1 2.3.4.4b HA E190D and Q226H mutations, picked up as minority variants in a patient, result in an inability to bind sialic acid.
    Virology. 2026;621:110949.
    PubMed         Abstract available


    Virus Res

  36. TJARNHAGE E, Vatsveen TK, Raki M, Nemazee D, et al
    Repurposing ALK Inhibitors as Influenza and Corona Virus Antivirals Targeting Lymphocyte Tyrosine Kinase (LTK).
    Virus Res. 2026 Jun 9:199759. doi: 10.1016/j.virusres.2026.199759.
    PubMed         Abstract available

My New Space

Most Popular Posts